CSP EXAM TEST (SPECIALTY PHARMACY)
WITH CORRECT ANSWERS PLUS DETAILED
RATIONALES|| GRADED A+|| FULLY
SOLVED!!|| LATEST UPDATE 2026
1. Specialty medications are typically characterized by:
A. Low cost and short-term use
B. High cost, complex handling, and chronic use
C. Over-the-counter availability
D. No monitoring requirements
Answer: B. High cost, complex handling, and chronic use
Rationale: Specialty drugs are high-cost therapies requiring special handling, monitoring, and
patient support.
2. The organization that administers the CSP credential is:
A. Pharmacy Technician Certification Board
B. National Association of Specialty Pharmacy
C. American Pharmacists Association
D. Accreditation Council for Pharmacy Education
Answer: B. National Association of Specialty Pharmacy
Rationale: NASP administers the Certified Specialty Pharmacist (CSP) credential.
3. REMS programs are designed to:
A. Increase drug pricing
B. Ensure safe use of high-risk medications
C. Replace FDA approval
D. Shorten clinical trials
Answer: B. Ensure safe use of high-risk medications
Rationale: Risk Evaluation and Mitigation Strategies (REMS) manage serious safety concerns.
,4. The agency that oversees REMS programs is:
A. Centers for Medicare & Medicaid Services
B. Food and Drug Administration
C. Drug Enforcement Administration
D. Department of Health and Human Services
Answer: B. Food and Drug Administration
Rationale: The FDA enforces REMS requirements.
5. Cold chain medications must typically be stored at:
A. -20°C
B. 0–2°C
C. 2–8°C
D. 10–15°C
Answer: C. 2–8°C
Rationale: Most refrigerated biologics require 2–8°C storage.
6. A prior authorization is primarily required to:
A. Increase copay
B. Verify medical necessity
C. Delay dispensing
D. Reduce pharmacy workload
Answer: B. Verify medical necessity
Rationale: Payers require PA to confirm appropriate use.
7. Orphan drugs are intended to treat:
A. Pediatric patients only
B. Rare diseases
C. Infectious diseases
D. Cosmetic conditions
Answer: B. Rare diseases
Rationale: Orphan Drug Act supports rare condition treatments.
, 8. Specialty pharmacies must track adherence primarily to:
A. Increase billing
B. Meet accreditation and improve outcomes
C. Replace prescribers
D. Avoid documentation
Answer: B. Meet accreditation and improve outcomes
Rationale: Adherence improves clinical and payer outcomes.
9. A biologic medication differs from a small molecule drug because it is:
A. Chemically synthesized only
B. Derived from living cells
C. Always oral
D. OTC
Answer: B. Derived from living cells
Rationale: Biologics are produced using biotechnology.
10. Limited distribution drugs are:
A. Available at all retail pharmacies
B. Restricted to certain specialty pharmacies
C. OTC only
D. Not FDA-approved
Answer: B. Restricted to certain specialty pharmacies
Rationale: Manufacturers control distribution for monitoring and safety.
CLINICAL MANAGEMENT
11. A common adverse effect of biologic immunotherapies is:
A. Hypoglycemia
B. Injection site reaction
WITH CORRECT ANSWERS PLUS DETAILED
RATIONALES|| GRADED A+|| FULLY
SOLVED!!|| LATEST UPDATE 2026
1. Specialty medications are typically characterized by:
A. Low cost and short-term use
B. High cost, complex handling, and chronic use
C. Over-the-counter availability
D. No monitoring requirements
Answer: B. High cost, complex handling, and chronic use
Rationale: Specialty drugs are high-cost therapies requiring special handling, monitoring, and
patient support.
2. The organization that administers the CSP credential is:
A. Pharmacy Technician Certification Board
B. National Association of Specialty Pharmacy
C. American Pharmacists Association
D. Accreditation Council for Pharmacy Education
Answer: B. National Association of Specialty Pharmacy
Rationale: NASP administers the Certified Specialty Pharmacist (CSP) credential.
3. REMS programs are designed to:
A. Increase drug pricing
B. Ensure safe use of high-risk medications
C. Replace FDA approval
D. Shorten clinical trials
Answer: B. Ensure safe use of high-risk medications
Rationale: Risk Evaluation and Mitigation Strategies (REMS) manage serious safety concerns.
,4. The agency that oversees REMS programs is:
A. Centers for Medicare & Medicaid Services
B. Food and Drug Administration
C. Drug Enforcement Administration
D. Department of Health and Human Services
Answer: B. Food and Drug Administration
Rationale: The FDA enforces REMS requirements.
5. Cold chain medications must typically be stored at:
A. -20°C
B. 0–2°C
C. 2–8°C
D. 10–15°C
Answer: C. 2–8°C
Rationale: Most refrigerated biologics require 2–8°C storage.
6. A prior authorization is primarily required to:
A. Increase copay
B. Verify medical necessity
C. Delay dispensing
D. Reduce pharmacy workload
Answer: B. Verify medical necessity
Rationale: Payers require PA to confirm appropriate use.
7. Orphan drugs are intended to treat:
A. Pediatric patients only
B. Rare diseases
C. Infectious diseases
D. Cosmetic conditions
Answer: B. Rare diseases
Rationale: Orphan Drug Act supports rare condition treatments.
, 8. Specialty pharmacies must track adherence primarily to:
A. Increase billing
B. Meet accreditation and improve outcomes
C. Replace prescribers
D. Avoid documentation
Answer: B. Meet accreditation and improve outcomes
Rationale: Adherence improves clinical and payer outcomes.
9. A biologic medication differs from a small molecule drug because it is:
A. Chemically synthesized only
B. Derived from living cells
C. Always oral
D. OTC
Answer: B. Derived from living cells
Rationale: Biologics are produced using biotechnology.
10. Limited distribution drugs are:
A. Available at all retail pharmacies
B. Restricted to certain specialty pharmacies
C. OTC only
D. Not FDA-approved
Answer: B. Restricted to certain specialty pharmacies
Rationale: Manufacturers control distribution for monitoring and safety.
CLINICAL MANAGEMENT
11. A common adverse effect of biologic immunotherapies is:
A. Hypoglycemia
B. Injection site reaction
